This technology presents a novel class of lipid nanoparticles engineered for targeted delivery of mRNA specifically to the pancreas following systemic administration.
Background: Effective delivery of RNA therapeutics to specific organs remains a significant challenge in biomedical research. The pancreas, in particular, has been a difficult target due to its complex anatomy and biological barriers. Diseases such as pancreatic cancer, pancreatitis, and various metabolic disorders could greatly benefit from targeted mRNA therapies, but limited delivery options have hindered progress in this area. This gap in targeted delivery methods motivated the development of specialized lipid nanoparticles that can navigate systemic circulation and selectively accumulate in pancreatic tissue.
Technology Overview: This innovation introduces a new class of sulfonium lipid nanoparticles uniquely designed to transport mRNA molecules directly to the pancreas. Unlike conventional lipid nanoparticles that distribute broadly or accumulate in organs such as the liver, these sulfonium-based nanoparticles exhibit enhanced specificity for pancreatic tissue. The technology leverages the chemical properties of sulfonium lipids to improve nanoparticle stability, cellular uptake, and endosomal escape within the pancreas. Upon systemic administration, these nanoparticles efficiently deliver their mRNA payload to pancreatic tissues, enabling precise modulation of gene expression. The technology's value lies in its ability to overcome long-standing obstacles in organ-specific nucleic acid delivery, making it a promising platform for treating pancreatic conditions through gene therapy. Its novel lipid composition ensures minimal off-target effects and potential for reduced systemic toxicity. Additionally, the development was supported by rigorous research funded by the National Institutes of Health, underscoring its scientific foundation and therapeutic potential.
https://suny.technologypublisher.com/files/sites/adobestock_1666014263.jpeg Photo for reference only, not a depiction of the invention.
Advantages: • Targeted delivery to the pancreas, enhancing therapeutic precision and effectiveness. • Improved nanoparticle stability and cellular uptake due to innovative sulfonium lipid chemistry. • Potential to treat hard-to-target diseases such as pancreatic cancer, pancreatitis, and metabolic disorders. • Reduced off-target effects and systemic toxicity compared to non-specific delivery methods. • Supported by peer-reviewed research and upcoming scientific presentations, substantiating its credibility.
Applications: • Delivery of mRNA-based therapeutics for the treatment of pancreatitis. • Delivery of mRNA-based therapeutics for the treatment of pancreatic cancer. • Targeted mRNA delivery to address metabolic disorders involving the pancreas. • Platform technology for gene therapy applications requiring pancreas-specific targeting. • Research tool for studying pancreatic disease mechanisms by modulating gene expression in vivo.
Intellectual Property Summary: Patent application filed
Stage of Development: 3-4 The technology is at an early stage of development, with proof-of-concept demonstrated in laboratory and initial preclinical models.
Licensing Status: This technology is available for licensing.